within Pharmacolibrary.Drugs.ATC.L;

model L04AJ02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.3333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 3000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00611,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0039900000000000005,
    k12             = 0.197,
    k21             = 0.197
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AJ02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ravulizumab is a recombinant humanized monoclonal antibody that inhibits the complement protein C5. It is used intravenously for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adults and children. It is an FDA- and EMA-approved drug, offering extended-duration complement inhibition.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with PNH following intravenous dosing; model applies to both sexes, typical adult patient.</p><h4>References</h4><ol><li><p>Chonat, S, et al., &amp; Kulasekararaj, AG (2024). Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria. <i>Blood advances</i> 8(11) 2813–2824. DOI:<a href=\"https://doi.org/10.1182/bloodadvances.2023012267\">10.1182/bloodadvances.2023012267</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38551806/\">https://pubmed.ncbi.nlm.nih.gov/38551806</a></p></li><li><p>Yenerel, MN, et al., &amp; Szer, J (2023). Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. <i>Advances in therapy</i> 40(1) 211–232. DOI:<a href=\"https://doi.org/10.1007/s12325-022-02339-3\">10.1007/s12325-022-02339-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36272026/\">https://pubmed.ncbi.nlm.nih.gov/36272026</a></p></li><li><p>Lafayette, R, et al., &amp; Barratt, J (2025). Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. <i>Journal of the American Society of Nephrology : JASN</i> 36(4) 645–656. DOI:<a href=\"https://doi.org/10.1681/ASN.0000000534\">10.1681/ASN.0000000534</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39455063/\">https://pubmed.ncbi.nlm.nih.gov/39455063</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AJ02;
